Home
Tag
Erasca, Inc.
1 article
Company News
Erasca Shares Fall 5% on Trial Data
Erasca shares fell about 5% in after‑hours trading after releasing Phase 1 data for its pan‑RAS drug ERAS‑0015. In KRAS G12X non‑small cell lung cancer, ERAS‑0015 achieved a 62% unconfirmed overall re